These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12544176)

  • 1. A prospective, open-label trial of olanzapine in adolescents with schizophrenia.
    Findling RL; McNamara NK; Youngstrom EA; Branicky LA; Demeter CA; Schulz SC
    J Am Acad Child Adolesc Psychiatry; 2003 Feb; 42(2):170-5. PubMed ID: 12544176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
    J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching outpatients with schizophrenia and related disorders on long-acting injectable antipsychotics to olanzapine: an open-label naturalistic pilot study.
    Labelle A; Bourget D; Boulay LJ; Ellis J; Tessier P
    J Clin Psychopharmacol; 2002 Dec; 22(6):545-53. PubMed ID: 12454553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial.
    Lindenmayer JP; Volavka J; Lieberman J; Sheitman B; Citrome L; Chakos M; Czobor P; Parker B; Iskander A
    J Clin Psychopharmacol; 2001 Aug; 21(4):448-53. PubMed ID: 11476131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
    Conley RR; Mahmoud R
    Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder.
    Frazier JA; Biederman J; Tohen M; Feldman PD; Jacobs TG; Toma V; Rater MA; Tarazi RA; Kim GS; Garfield SB; Sohma M; Gonzalez-Heydrich J; Risser RC; Nowlin ZM
    J Child Adolesc Psychopharmacol; 2001; 11(3):239-50. PubMed ID: 11642474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.
    Dossenbach MR; Kratky P; Schneidman M; Grundy SL; Metcalfe S; Tollefson GD; Belmaker RH
    J Clin Psychiatry; 2001; 62 Suppl 2():28-34. PubMed ID: 11232749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents.
    Kumra S; Jacobsen LK; Lenane M; Karp BI; Frazier JA; Smith AK; Bedwell J; Lee P; Malanga CJ; Hamburger S; Rapoport JL
    J Am Acad Child Adolesc Psychiatry; 1998 Apr; 37(4):377-85. PubMed ID: 9549958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study.
    Dittmann RW; Meyer E; Freisleder FJ; Remschmidt H; Mehler-Wex C; Junghanss J; Hagenah U; Schulte-Markwort M; Poustka F; Schmidt MH; Schulz E; Mästele A; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2008 Feb; 18(1):54-69. PubMed ID: 18294089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
    Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
    J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.
    Revicki DA; Genduso LA; Hamilton SH; Ganoczy D; Beasley CM
    Qual Life Res; 1999 Aug; 8(5):417-26. PubMed ID: 10474283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia.
    Godleski LS; Goldsmith LJ; Vieweg WV; Zettwoch NC; Stikovac DM; Lewis SJ
    J Clin Psychiatry; 2003 Feb; 64(2):119-22. PubMed ID: 12633119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients.
    Bobes J; Gibert J; Ciudad A; Alvarez E; Cañas F; Carrasco JL; Gascón J; Gómez JC; Gutiérrez M
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):473-81. PubMed ID: 12691783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders.
    Lambert M; Holzbach R; Moritz S; Postel N; Krausz M; Naber D
    Int Clin Psychopharmacol; 2003 Sep; 18(5):251-60. PubMed ID: 12920385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up.
    Karagianis JL; LeDrew KK; Walker DJ
    Curr Med Res Opin; 2003; 19(6):473-80. PubMed ID: 14594518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine in Chinese treatment-resistant patients with schizophrenia: an open-label, prospective trial.
    Chiu NY; Yang YK; Chen PS; Chang CC; Lee IH; Lee JR
    Psychiatry Clin Neurosci; 2003 Oct; 57(5):478-84. PubMed ID: 12950701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine versus haloperidol treatment in first-episode psychosis.
    Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
    Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia.
    Bitter I; Dossenbach MR; Brook S; Feldman PD; Metcalfe S; Gagiano CA; Füredi J; Bartko G; Janka Z; Banki CM; Kovacs G; Breier A;
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):173-80. PubMed ID: 14687871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
    Kinon BJ; Roychowdhury SM; Milton DR; Hill AL
    J Clin Psychiatry; 2001; 62 Suppl 2():17-21. PubMed ID: 11232746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study.
    Vernal DL; Kapoor S; Al-Jadiri A; Sheridan EM; Borenstein Y; Mormando C; David L; Singh S; Seidman AJ; Carbon M; Gerstenberg M; Saito E; Kane JM; Steinhausen HC; Correll CU
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):535-47. PubMed ID: 26375767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.